[Federal Register Volume 86, Number 129 (Friday, July 9, 2021)]
[Notices]
[Pages 36283-36284]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14637]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-Z-0025]


Requests for Proposals for Insulin Reimportation and Personal 
Prescription Drug Importation; Withdrawal

AGENCY: Food and Drug Administration (FDA), Department of Health and 
Human Services (HHS).

ACTION: Notice; withdrawal.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (Department or 
HHS) is announcing the withdrawal of a notice published in the Federal 
Register on January 21, 2021, entitled ``Requests for Proposals for 
Insulin Reimportation and Personal Prescription Drug Importation.'' HHS 
also withdraws the requests for proposals issued on its website on 
September 24, 2020, and revised on January 13, 2021, and ends the 
period for submission of proposals in response to the requests for 
proposals.

DATES: The notice published in the Federal Register on January 21, 
2021, at 86 FR 6343, is withdrawn as of July 9, 2021.

FOR FURTHER INFORMATION CONTACT: Katelyn Mineo, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6222, Silver Spring, MD 20993, 301-796-
1054.

SUPPLEMENTARY INFORMATION: On September 24, 2020, HHS issued two 
requests for proposals for the reimportation of insulin and the 
personal importation of prescription drugs (collectively, the RFPs) and 
posted related ``Frequently Asked Questions'' documents (FAQs) on its 
website. On January 21, 2021, HHS published a notice in the Federal 
Register entitled ``Requests for Proposals for Insulin Reimportation 
and Personal Prescription Drug Importation'' (the HHS Notice) (86 FR 
6343). The HHS Notice referred to revised versions

[[Page 36284]]

of the RFPs. The responses to the RFPs were directed in the HHS Notice 
and in the RFP for Personal Prescription Drug Importation issued on 
September 24, 2020, and revised on January 13, 2021, to be submitted to 
an HHS email address: <a href="/cdn-cgi/l/email-protection#ddb4b0adb2afa99db5b5aef3bab2ab"><span class="__cf_email__" data-cfemail="e28b8f928d9096a28a8a91cc858d94">[email protected]</span></a>, while the RFP for Insulin 
Reimportation Programs issued on September 24, 2020, and revised on 
January 13, 2021, directed that responses be sent to <a href="/cdn-cgi/l/email-protection#01686c716e7375416969722f666e77"><span class="__cf_email__" data-cfemail="543d39243b2620143c3c277a333b22">[email protected]</span></a> and 
to the Director of the FDA Import Division in the region of the 
intended port of entry. The Department is not aware that any proposals 
were received in response to the HHS Notice or RFPs. The HHS Notice, 
RFPs, and FAQs are withdrawn. All website statements and other informal 
issuances with respect to the HHS Notice and RFPs are also withdrawn. 
Accordingly, no proposals submitted to HHS or FDA in response to the 
HHS Notice or RFPs on or after July 9, 2021 will be considered by HHS 
or FDA. HHS intends to consider alternatives to the RFPs.

    Dated: June 11, 2021.
Janet Woodcock,
Acting Commissioner of Food and Drugs.

    Dated: June 28, 2021.
Xavier Becerra,
Secretary, Department of Health and Human Services.
[FR Doc. 2021-14637 Filed 7-8-21; 8:45 am]
BILLING CODE 4164-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>